Lee's Pharmaceutical Holdings Limited (HK:0950)
:0950
Want to see HK:0950 full AI Analyst Report?
0950 Stock Chart & Stats
HK$1.55
-HK$0.01(-0.76%)
At close: 4:00 PM EST
HK$1.55
-HK$0.01(-0.76%)
Day’s Range― - ―
52-Week RangeHK$0.99 - HK$2.70
Previous CloseN/A
Volume7.00K
Average Volume (3M)5.40M
Market Cap
HK$612.39M
Enterprise ValueHK$625.76M
Total Cash (Recent Filing)HK$349.90M
Total Debt (Recent Filing)HK$310.27M
Price to Earnings (P/E)6.7
Beta0.80
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.92%
Share Statistics
EPS (TTM)0.14
Shares Outstanding588,835,300
10 Day Avg. Volume4,101,801
30 Day Avg. Volume5,400,283
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.44
Price to Sales (P/S)0.62
P/FCF Ratio8.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage / Strong Balance SheetSustained low debt-to-equity (≈0.08–0.15) and rising equity create long-term financial flexibility. This reduces refinancing risk, supports investment in R&D/commercialization, and cushions the business through revenue cyclicality, preserving strategic optionality over months.
Healthy Gross Margins And Positive Net ProfitabilitySustained gross margins (~51%) and mid-single-digit net margins indicate underlying product-level pricing power and cost structure that support profitability. Even with operating variability, durable margins allow the company to reinvest in pipeline and commercialization over the medium term.
Improving Operating Cash FlowRising operating cash flow demonstrates stronger cash generation from core operations, enabling funding of working capital, R&D, and selective business development without heavy reliance on external funding. This supports sustainable operations across upcoming quarters.
Bears Say
Margin Compression And Uneven Operating ResultsVisible margin squeeze (operating margin fell from ~8% to ~4%) signals pressure on pricing, higher costs, or product mix shifts. Persisting compression would erode reinvestment capacity and returns, making earnings less predictable over the next several quarters.
Volatile And Weak Free Cash FlowIntermittent negative FCF and large swings reduce certainty around internal funding for R&D and commercialization. Volatile cash conversion increases reliance on equity or debt for growth initiatives, raising execution risk and limiting durable capital deployment.
Inconsistent Revenue Growth TrendFluctuating top-line performance implies dependence on a limited product set, lumpy licensing milestones, or uneven market access. This weakens visibility for forecasting and strategic planning, raising the risk that shortfalls persist across multiple reporting periods.
Lee's Pharmaceutical Holdings Limited News
0950 FAQ
What was Lee's Pharmaceutical Holdings Limited’s price range in the past 12 months?
Lee's Pharmaceutical Holdings Limited lowest stock price was HK$0.99 and its highest was HK$2.70 in the past 12 months.
What is Lee's Pharmaceutical Holdings Limited’s market cap?
Lee's Pharmaceutical Holdings Limited’s market cap is HK$612.39M.
When is Lee's Pharmaceutical Holdings Limited’s upcoming earnings report date?
Lee's Pharmaceutical Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 67 days.
How were Lee's Pharmaceutical Holdings Limited’s earnings last quarter?
Lee's Pharmaceutical Holdings Limited released its earnings results on Mar 30, 2026. The company reported HK$0.042 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.042.
Is Lee's Pharmaceutical Holdings Limited overvalued?
According to Wall Street analysts Lee's Pharmaceutical Holdings Limited’s price is currently Overvalued.
Does Lee's Pharmaceutical Holdings Limited pay dividends?
Lee's Pharmaceutical Holdings Limited pays a Quarterly dividend of HK$0.023 which represents an annual dividend yield of 2.92%. See more information on Lee's Pharmaceutical Holdings Limited dividends here
What is Lee's Pharmaceutical Holdings Limited’s EPS estimate?
Lee's Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lee's Pharmaceutical Holdings Limited have?
Lee's Pharmaceutical Holdings Limited has 588,835,300 shares outstanding.
What happened to Lee's Pharmaceutical Holdings Limited’s price movement after its last earnings report?
Lee's Pharmaceutical Holdings Limited reported an EPS of HK$0.042 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.549%.
Which hedge fund is a major shareholder of Lee's Pharmaceutical Holdings Limited?
Currently, no hedge funds are holding shares in HK:0950
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lee's Pharmaceutical Holdings Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.67%
12-Months-Change
Fundamentals
Return on Equity
4.85%
Trailing 12-Months
Asset Growth
32.32%
Trailing 12-Months
Company Description
Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Technical Analysis
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―
Pak Fah Yeow International Limited
―
Jacobson Pharma Corporation Limited
―
Options Prices
Currently, No data available
---